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In 1994, Bonetti et al introduced the concept of a family of tumors that includes a clear cell sugar tumor (CCST) of the lung and angiomyolipoma 
(AML) of the kidney, and is characterized by the prest
ence of a peculiar muscle cell that expresses different 
melanomatassociated antigens such as HMB45 and 
HMSAt1.1 In 1996, Zamboni et al described a case of 
a pancreatic tumor that consisted of  “a population of 
large epithelioid cells with clear or eosinophilic, granular 
cytoplasm, rich in glycogen, with nuclear pleomorphism 
and no mitotic activity,” and regarded it as a member 
of a new family of tumors named ‘PEComas’.2 Cases of 
PEComa arising at various sites have been increasingly 
reported over the past decade, and it has now become a 
welltaccepted entity. The World Health Organization 
defines PEComas as “mesenchymal tumors composed 
of histologically and immunohistochemically distinct
tive perivascular epithelioid cells”, which include AML, 
CCST of the lung, lymphangioleiomyomatosis (LAM), 
clear cell myomelanocytic tumors of the falciform ligat
ment/ligament teres, and other unusual clear cell tut
mors at various locations.3 PEComas other than AML, 
CCST or LAM are rare mesenchymal tumors, and the 
uterus is the most commonly affected site. To the best 
of our knowledge, 44 cases of PEComa of the uterus 
have been reported in the English literature, of which 
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perivascular epithelioid cell tumor (pecoma) is a rare mesenchymal tumor composed of histologically 
and immunohistochemically distinctive perivascular epithelioid cells (pecs). both benign and malignant 
tumors have been identified, but the criteria for diagnosis of malignancy have not been fully established 
due to the rarity of the tumor. We report on a case of uterine pecoma in a 33-year old woman with 
lymph node metastasis at presentation. the tumor had the characteristic histologic features of pecoma 
with cytologic atypia, mitotic activity of 2/10 high power field (hpf), and necrosis; it exhibited im-
munopositivity for hmb-45, calponin and desmin and was negative for melan-a. the patient received 
neoadjuvant chemotherapy, debulking surgery and adjuvant chemotherapy. no evidence of recurrence 
or metastasis was apparent 8 months after surgery. 
13 cases were malignant.4t12 We describe a case of mat
lignant PEComa of the uterus.
CASE
Our patient was a 33tyeartold previously healthy 
gravida 1 para 1 oriental woman who presented with 
menorrhagia and dysmenorrhea that had been ongoing 
for months. An ultrasound scan revealed a large tumor 
measuring 8.1×7.2 × 6.4 cm at the posterior wall of the 
uterine corpus. With a clinical diagnosis of leiomyoma, 
the patient first underwent laparoscopic tumor excit
sion, and intraoperative histologic examination showed 
a uterine sarcoma and left retroperitoneal lymph node 
metastasis. An MRI after the first surgery showed an 
irregular infiltrative tumor measuring 10×8×6 cm on 
the posterior uterine wall and extending to the left parat
metrium. The patient was given 3 courses of a combinat
tion neoadjuvant chemotherapy (C/T), including epit
rubicin, cisplatin and ifosfamide, after which the tumor 
exhibited relative shrinkage; she then underwent total 
hysterectomy, bilateral salpingotoophorectomy (BSO), 
omentectomy, bilateral pelvic and parataortic lymphadt
enectomy, and received another two courses of adjuvant 
chemotherapy including epirubicin, cisplatin and ifost
famide. No recurrence or distant metastasis was appart
ent 8 months after the operation.
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The specimens obtained after surgery were fixed 
in 10% buffered formalin and processed for histot
logic examination by conventional methods. The sect
tions were stained with hemotoxylin and eosin stain. 
Immunohistochemical staining was carried out on 
paraffin sections with a panel of antibodies including 
calponin (Dako, clone: CALP), desmin (Dako, clone: 
D33), HMBt45 (Dako), melantA (Dako, clone: A103), 
and CD10 (Thermo) using an autostaining system 
(Ventana Medical System, Tucson, Arizona). Clinical 
information was obtained from the medical records.
The first resected specimen consisted of several 
tumorous fragments measuring up to 6×4.5×4.5 cm 
in size. On cutting, sections were multilobular, gray, 
and elastic with central necrosis. The second resected 
specimen consisted of the uterus with bilateral adnexae, 
omentum, bilateral pelvic and parataortic lymph nodes. 
The uterus measured 10×7×4.5 cm in size, and several 
infiltrative tumors in the myometrium measuring up to 
1.7×1.5×1.5 cm in size were located in the lower segt
ment of the posterior uterine wall. On cutting, sections 
were gray and elastic with necrosis. The bilateral adnext
ae were not remarkable.
The tumors from the two specimens revealed simit
lar morphologic features; they showed multinodular 
growth of spindle to epithelioid cells with clear to eot
sinophilic cytoplasm and oval, hyperchromatic nuclei 
(Figure 1 and 2). The cytologic atypia was moderate 
to severe, and the tumor cells showed marked pleot
morphism. Frequent large bizarre cells were present, 
and the foci of hemorrhage and necrosis were seen. 
The mitotic activity was 2/10 HPF, and lymphovascut
lar permeation was seen. Immunohistochemical study 
demonstrated that the tumor cells were diffuse positive 
for calponin, desmin (Figure 3) and HMBt45 (Figure 
4), and negative for melantA and CD10.
DISCuSSION
PEC was first described in 1943 by Apitz in terms of 
the epithelioid feature in renal angiomyolipoma.13 It is 
characterized by an epithelioid appearance with a clear 
to granular cytoplasm, round to oval, centrallytlocated 
nuclei and a perivascular distribution. PEC can show 
any degree of atypia. Until recently, there has been no 
known normal counterpart of PEC. PEComa is now a 
widelytaccepted type of neoplasm. Some authors still 
doubt the existence of this entity due to the overlapping 
morphologic and immunologic features with smooth 
muscle tumors and the absence of a normal countert
part for PEC; however, increasing genetic evidence has 
shown PEComa to be a distinct type of neoplasm.14t16 
About 10% of reported uterine PEComas have been 
Figure 1. Tumor shows focal tongue-like nodular structure 
(hematoxylin and eosin ×40).
Figure 2. Tumor is composed of spindle to epithelioid cells with 
clear to eosinophilic cytoplasms and oval, hyperchromatic 
nuclei. Large bizarre cells are seen (hematoxylin and eosin ×400).
Figure 3. Tumor is positive for desmin (immunostaining, ×100).
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related to the tuberous sclerosis complex (TSC), an 
autosomal dominant disease characterized by mental 
retardation, seizures and the development of tumors in 
multiple organs. However, our patient had no personal 
or family history of TSC.
Differential diagnoses of uterine PEComa include 
epithelioid leiomyosarcoma and endometrial strot
mal sarcoma (ESS). Epithelioid leiomyosarcoma and 
PEComa have many overlapping histologic features: 
both tumors are composed of spindle and/or epithelit
oid cells with variable stromal hyalinization; however, 
PEComa more often exhibits pale eosinophilic to clear 
cytoplasm, round to oval nuclei, and a prominent capt
illary network. Immunohistochemically, both tumors 
show variable reactivity for smooth muscle markers 
and melanocytic markers. Nearly all epithelioid smooth 
muscle tumors show immunoreactivity for smooth 
muscle actin, while 73% of PEComas show reactivt
ity. All PEComas show immunoreactivity for at least 
one melanocytic marker, while only 56% of epithelioid 
smooth muscle tumors do.17 Epithelioid leiomyosarcot
ma typically shows focal and patchy reactivity for melat
nocytic markers, but this may also be seen in PEComa. 
The cotexpression of smooth muscle markers and met
lanocytic markers in PEComas and smooth muscle 
tumors may imply that they have similar lines of dift
ferentiation. If a conventional smooth muscle tumor is 
encountered, one should not diagnose it as a PEComa 
owing to its melanocytic immunoreactivity. In our case, 
the tumor showed characteristic morphologic features 
of a PEComa, such as epithelioid cells with clear cytot
plasm and oval nuclei, as well as immunohistochemical 
features. ESS may show irregular tonguetlike nodular 
extensions into the myometrium, and the endometrit
um is usually involved; the tumor is typically composed 
of spindle to polygonal cells and shows reactivity for 
CD10. In our case the tumor did not resemble ESS, 
either histologically or immunohistochemically. 
Due to the rarity of cases of PEComa, the criteria 
for the diagnosis of malignancy have not yet been fully 
established. The uterus is the most frequently affected 
organ, but only 13 cases showing malignant clinical 
features have been reported (Table 1). Folpe et al ret
ported 26 cases of PEComa of soft tissue and gynecot
logic origin in 2005,6 and proposed provisional criteria 
that could be used to classify PEComa into “benign,” 
“of uncertain malignant potential,” and “malignant” 
categories. Benign tumors were classed as those that 
had no worrisome features (i.e., <5 cm, nontinfiltrat
tive, nothigh nuclear grade and cellularity, mitotic rate 
≤1/50 HPF, no necrosis or vascular invasion). Tumors 
of uncertain malignant potential were classed as havt
ing either nuclear pleomorphism/multinucleated giant 
cells only or being of a size >5 cm only, and those with 
two or more worrisome histologic features should be 
considered malignant. The application of these criteria 
to the uterus is still questionable, but it seems to be the 
most optimal classification for the moment. Our case 
had all the worrisome histologic features presented by 
Folpe. In 2008, Fadare reviewed 31 cases of previously 
reported uterine PEComas, and routine pathologic pat
rameters were evaluated for the determination of mat
lignant potential.18 The study concluded that the only 
features that indicate a definite potential for aggressive 
behavior are a mitotic count >1/10 HPF and/or coagt
ulative necrosis, while cytologic atypia should be cont
sidered to be at least an indication of uncertain maligt
nant potential. Although the size of the malignant and 
nonmalignant groups showed significant differences, 
using a size threshold to distinguish between them was 
not advised. 
The management of PEComas is quite variable. 
Surgical excision is the most common approach for 
malignant uterine PEComa; some patients have also 
undergone R/T and/or C/T or even hormone therapy, 
but their effectiveness is still questionable. In our case, 
the patient received neoadjuvant C/T, but the effectivet
ness was not very significant. Three courses of adjuvant 
C/T were administered after surgery, and a longer folt
lowtup time is needed in order to evaluate the effectivet
ness of the C/T. A therapeutic clinical trial for uterine 
PEComa is difficult to establish due to its rarity, but it 
appears that more and more cases have been reported 
since the turn of the century, and therefore a therapeut
tic trial may be able to be performed in the future. 
We have reported herein the case of a uterine 
PEComa with both a malignant histologic picture and 
Figure 4. Tumor is positive for HMB-45 (immunostaining, ×100).
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Table 1. reported cases of uterine PeComa with malignant behavior.
   Reference Age Symptoms Management Outcome TSC
   Bonetti (2001)12 19 abdominal pain
Hysterectomy/ BSO/ pelvic and 
inguinal lymphadenopathy, 
vaginal cuff excision, 
adjuvant C/T and r/T
Lymph node metastases and 
vaginal extension at presentation; 
bone and lung metastases at 
18 months; loss of follow-up
no
   Bonetti (2001)12 41 abdominal mass Hysterectomy/ BSO Ovarian metastases at presentation; ned at 6 months Yes
   dimmler (2003)10 61 abnormal uterine bleeding Hysterectomy Lung metastases at 7 years no
   greene (2003)11 79 Vague abdominal symptoms Hysterectomy/ BSO, surgical debulking for recurrent tumor
Pelvic and colonic mesenteric 
recurrence at 2 years; dOd at 
several months later
no
   Bosincu (2005)8 59 Hemoperitoneum Hysterectomy/ BSO, omentectomy Pelvic recurrence at 6 months; dOd at 1year no
   Bosincu (2005)8 48 abnormal uterine bleeding gnrH analogues, hysterectomy, Tamoxifen therapy ned at 36 months no
   Fukunaga (2005)9 40 abnormal uterine bleeding Hysterectomy/BSO, omentectomy, adjuvant C/T and r/T
Ovarian and omental 
metastases at presentation, 
dOd at 16 months
no
   Jeon (2005)7 9 abdominal pain and vaginal spotting
neoadjuvant C/T, hysterectomy, 
lymphadenectomy, adjuvant
C/T and r/T
Lymph node metastases at 
presentation, ned at 18 months no
   Folpe (2005)6 59 na adjuvant C/T
Liver and lung metastases at 30 
months; alive with metastases at 
30 months
no
   Folpe (2005)6 56 na adjuvant C/T and r/T
Lung and bone metastases at 11 
months; alive with metastases at 
11 months
no
   Folpe (2005)6 36 na Hysterectomy, adjuvant C/T
Lung metastases at 12 months; 
liver metastases at 36 months; 
dOd at 39 months
no
   Liang (2007)5 59 abnormal uterine bleeding
Hysterectomy/BSO/Pelvic and 
para-aortic lymphadenenctomy, 
omentectomy, appendectomy, 
hormonal therapy
extension into endocervix at 
presentation; ned at 10 months Yes
   armah (2007)4 52 na Hysterectomy/BSO, resection of renal and pulmonary metastases
renal and pulmonary metastases 
at 7 years; ned at 15 months 
after metastases
no
   Present (2009) 33 abnormal uterine bleeding
Partial tumor excision, 
neoadjuvant C/T; hysterectomy/ 
BSO/ omentectomy/ pelvic and 
para-aortic lymphadenectomy; 
adjuvant C/T
Lymph node metastases at 
presentation; ned at 8 months no
r/T radiotherapy; C/T chemotherapy; BSO bilateral salpingo-oopherectomy; ned no evidence of disease; dOd dead of disease; na not available
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clinically aggressive behavior. Immunohistochemical 
staining of HMBt45 should be performed on uterine 
epithelioid cell tumors with clear or pale eosinophilic 
cytoplasm in order to avoid misdiagnosis. The criteria 
for diagnosis of malignancy in the uterus have not fully 
been established due to the rarity of reported cases. We 
consider that all uterine PEComas should at least be 
regarded as tumors of uncertain malignant potential, 
and all patients diagnosed with uterine PEComa ret
gardless of histologic features should receive longtterm 
followtup in order to determine the biological behavior 
of the tumor.
1. Bonetti F, Pea M, Martignoni g, doglioni C, 
Zamboni g, Capelli P, rimondi P, andrion a.: Clear 
cell (“sugar”) tumor of the lung is a lesion strictly 
related to angiomyolipoma--the concept of a fam-
ily of lesions characterized by the presence of the 
perivascular epithelioid cells (PeC). Pathology. 
1994; 26:230-6.
2. Zamboni g, Pea M, Martignoni g, et al. Clear cell 
“sugar” tumor of the pancreas: a novel member 
of the family of lesions characterized by the pres-
ence of perivascular epithelioid cells. am J Surg 
Pathol. 1996;20:722-30.
3. Folpe aL. neoplasms with perivascular epitheli-
oid cell differentiation (PeComa). in Fletcher CdM, 
Unni KK, epstein J, Merten F. Pathology and genet-
ics of tumours of soft tissue and bone. iarC Press, 
Lyon, 2002:221-2.
4. armah HB, Parwani aV: Malignant perivascu-
lar epithelioid cell tumor (PeComa) of the uterus 
with late renal and pulmonary metastases: a case 
report with review of the literature. diagn Pathol. 
2007;2:45.
5. Liang SX, Pearl M, Liu J, Hwang S, Tornos C: 
“Malignant” uterine perivascular epithelioid cell 
tumor, pelvic lymph node lymphangioleiomyoma-
tosis, and gynecological pecomatosis in a patient 
with tuberous sclerosis: a case report and review 
of the literature. int J gynecol Pathol. 2008;27:86-
90.
6. Folpe aL, Mentzel T, Lehr Ha, Fisher C, Balzer 
BL, Weiss SW: Perivascular epithelioid cell neo-
plasms of soft tissue and gynecologic origin: a 
clinicopathologic study of 26 cases and review of 
the literature. am J Surg Pathol. 2005;29:1558-75.
7. Jeon iS, Lee SM: Multimodal treatment using 
surgery, radiotherapy, and chemotherapy in a pa-
tient with a perivascular epithelioid cell tumor of 
the uterus. J Pediatr Hematol Oncol. 2005;27:681-
4.
8. Bosincu L, rocca PC, Martignoni g, nogales FF, 
Longa L, Maccioni a, Massarelli g: Perivascular 
epithelioid cell (PeC) tumors of the uterus: a clini-
copathologic study of two cases with aggressive 
features. Mod Pathol 2005;18:1336-42.
9. Fukunaga M: Perivascular epithelioid cell tumor 
of the uterus: report of four cases. int J gynecol 
Pathol. 2005,24:341-6.
10. dimmler a, Seitz g, Hohenberger W, Kirchner 
T, Faller g: Late pulmonary metastasis in uterine 
PeComa. J Clin Pathol. 2003;56:627-8.
11. greene La, Mount SL, Schned ar, Cooper K: 
recurrent perivascular epithelioid cell tumor of 
the uterus (PeComa): an immunohistochemical 
study and review of the literature. gynecol Oncol. 
2003;90:677-81.
12. Bonetti F, Martignoni g, Colato C, Manfrin e, 
gambacorta M, Faleri M, Bacchi C, Sin VC, Wong 
nL, Coady M, Chan JK: abdominopelvic sarcoma 
of perivascular epithelioid cells. report of four 
cases in young women, one with tuberous scle-
rosis. Mod Pathol. 2001;14:563-8.
13. apitz, K. die geschwulste und gewebsmiss-
bildungen der nierenrinde. ii Mitteilung. die 
mesenchymalen neubildungen. [The Tumors 
and Tissue abnormalities of the renal Cortex. ii 
Communication. The Mesenchymal neoplasms]. 
Virchows arch. 1943;311:306-27.
14. Pan CC, Chung MY, ng KF, Liu CY, Wang JS, 
Chai CY, Huang SH, Chen PC, Ho dM. Constant 
allelic alteration on chromosome 16p (TSC2 gene) 
in perivascular epithelioid cell tumour (PeComa): 
genetic evidence for the relationship of PeComa 
with angiomyolipoma. J Pathol. 2008;214:387-93.
15.  Pan CC, Jong YJ, Chai CY, Huang SH, Chen 
YJ. Comparative genomic hybridization study of 
perivascular epithelioid cell tumor: molecular 
genetic evidence of perivascular epithelioid cell 
tumor as a distinctive neoplasm. Hum Pathol. 
2006;37:606-12.
16. Kenerson H, Folpe aL, Takayama TK, Yeung 
rS. activation of the mTOr pathway in sporadic 
angiomyolipomas and other perivascular epitheli-
oid cell neoplasms. Hum Pathol. 2007;38:1361-71.
17. Fadare O. Uterine PeComa: appraisal of a con-
troversial and increasingly reported mesenchy-
mal neoplasm. int Semin Surg Oncol. 2008;5:7.
18. Fadare O. Perivascular epithelioid cell tumor 
(PeComa) of the uterus: an outcome-based clini-
copathologic analysis of 41 reported cases. adv 
anat Pathol. 2008;15:63-75.
REfERENCES
